[ad_1]
The pharmaceutical company Sanofi
surprisingly good third quarter delivered and investors
enthusiastic. Adjusted sales and earnings outperformed
Expectations. For the past year, Sanofi is now a little more optimistic,
the stock gained more than 4% Wednesday morning.
Sanofi achieved adjusted sales and adjusted earnings
thanks to the good business of the biotechnology division Genzyme and
Properly high in developing countries. The product was in the quarter
increased by 3.7% to 9.392 billion euros, the group
announced Wednesday in Paris.
Sanofi is in the third quarter on a new growth path
Olivier Brandicourt, boss of the company
Message. The group is now good for future growth
established.
Brandicourt relies in particular on the agent Dupixent, for
Sanofi after approval for the treatment of atopic dermatitis
now the United States also get the green light for the treatment of asthma
at. In the third quarter, revenues with funds exceeded
Analysts' expectations slightly.
The drug comes from Genzyme Laboratories. In the division
become treatments for rare and difficult to treat diseases
developed. It's also thanks to the consolidation of the new purchase
The most important growth factor bioveratively. Genzyme has registered one
strong sales increase of more than a third.
Developing country incomes jumped by more than 10%
Percentage without exchange rate effects. Also in China, the sale of
The drugs are good. The last activity of weak vaccines also progressed
net, excluding currency effects, growth is 8.2%
Percent. Revenues in the second quarter were still around 15.7
Percentage of return. The vaccines business is more than a match for Sanofi
Fifth of the turnover.
Adjusted net earnings per share amounted to 1.84 euro and increased
therefore more than 8%. Sanofi now has a full year
this indicator of a plus between 4 and 5%.
Previously, the range was 3 to 5%. The bottom line was
a special effect of the sale of the European brand
Generic company (Zentiva) for strong revenue growth. the
Profits increased by nearly 46% to about 2.3 billion
Euro./stk/tav
ISIN FR0000120578
AXC0127 2018-10-31 / 11: 17
Copyright dpa-AFX Business News GmbH. All rights reserved. Redistribution, republication or permanent storage without the express and prior permission of dpa-AFX is not permitted.
[ad_2]
Source link
